Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image
Average (ratings)
No ratings
Your rating

Disclosure:FM is on the European Cardiology Review editorial board.



Published online:

Correspondence Details:Felipe Martinez, Cordoba National University, Av Colόn 2057. Cordoba X5003DSE, Argentina. E: dr.martinez@usa.net

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

People with diabetes have a higher than average risk of developing cardiovascular disease.1,2 The mechanisms underlying the relationship between diabetes and cardiovascular disease are not fully understood, but recent studies have explored this rapidly evolving research field.3 As a result, there is a clear need for cardiologists to improve and increase their involvement in the therapeutic management of diabetes. In this volume of European Cardiology Review, Ahmad et al. provide an update on the most recent pharmacological advances and mechanisms linking diabetes and cardiovascular disease, with a focus on clinical practice.4

A number of therapies in cardiology improve surrogate measures of disease, but do not necessarily translate to better patient outcomes.5 It was previously assumed that strict glucose control, reflected by improved HbA1c, would lead not only to reductions in microvascular outcomes but would also reduce cardiovascular complications.6 After some trials with hypoglycaemic drugs demonstrated an increase in major adverse cardiovascular events (MACE) and, in particular, heart failure-related outcomes, some of the main international regulatory agencies required that all antidiabetic therapies demonstrate cardiovascular safety when compared with placebo.7–9 Since that decision, a long list of compounds have been designed to evaluate not only the antidiabetic/metabolic effects, but also cardiovascular benefits and safety of diabetes drugs. The results of these trials showed surprising and important positive impacts in MACE, particularly in heart failure outcomes. Two groups of drugs are changing the management of diabetes and cardiovascular disease: glucagon-like peptide-1 (GLP-1) receptor agonists, also known as incretin mimetics, and sodiumglucose transporter 2 (SGLT2) inhibitors, also known as gliflozins.9 This editorial is focused on these two groups of drugs.

Glucagon-like Peptide-1 Receptor Agonists

GLP-1 receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations; inconsistent effects on cardiovascular outcomes have been reported by Ahmad et al. after they analysed seven cardiovascular outcome studies evaluating GLP-1 receptor agonists, some demonstrating benefits in cardiovascular outcomes.4 These studies include large and well-known trials, such as LEADER (with liraglutide), SUSTAIN-6 (with semaglutide), EXSCEL (with exenatide), ELIXA (with lixisenatide) and HARMONY (with albiglutide).10–14 More than 50,000 diabetic patients were randomised in those trials, and they generally demonstrated consistent results of reduced incidence of MACE.15

In a meta-analysis by Kristensen et al., GLP-1 receptor agonist treatment reduced MACE by 12% (HR 0.88, 95% CI [0.82–0.94], p<0.0001), with no evidence of treatment heterogeneity across the subgroups examined.16 The results also showed an improvement in renal outcomes. They observed a reduction in the composite of new-onset macroalbuminuria, estimated glomerular filtration rate, progression to end-stage kidney disease and death attributable to kidney causes by 17%.

It has been demonstrated that these drugs reduce cardiovascular outcomes in people with diabetes, and there are ongoing trials investigating if the same benefits occur in people without diabetes.

SGLT2 Inhibitors: The New Star

Recent trials with SGLT2 inhibitors, have shown that this group of drugs is emerging as a new and viable option for preventing and treating cardiac and renal dysfunction.17 SGLT-2 inhibitors were the first glucose-lowering drugs to show a reduction in MACE in people with type 2 diabetes and at high cardiovascular risk, according to the results of the EMPA-REG OUTCOME trial.18,19 Another trial, CANVAS, showed similar results for people with diabetes.20 Both trials demonstrated a significant decrease in the rate of heart failure-associated hospitalisation and mortality. Other large studies, such as DECLARE–TIMI 58 (with dapaglifozine), were included in a meta-analysis by Zelniker et al. that demonstrated consistency of the results.21,22 More recently, the VERTIS trial of ertruglifozine demonstrated some similar findings.23 In all cases, the study populations only included subjects with diabetes and there was an observed decrease in MACE in patients receiving SGLT2 inhibitors, albeit with some differences. Registries of people with diabetes patients have also demonstrated that those treated with SGLT2 inhibitors show a lower morbidity and mortality compared with those treated with other antidiabetic drugs, indicating that the results of clinical trials are similar to those observed in real world clinical practice.24,25

SGLT2 inhibitors were initially thought to provide the most benefit to patients with heart failure and then clinical trials then began to test them in the general population. The first of these studies was DAPA-HF, which randomised 4,744 patients with left ventricular ejection fraction ≤40% and symptomatic heart failure to dapagliflozin versus placebo.26 The primary outcome was a composite of worsening heart failure (hospitalisation or an urgent hospital visit resulting in IV therapy for heart failure) or cardiovascular death. This endpoint was significantly less in the dapagliflozin arm (HR: 0.74, 95% CI [0.65–0.85]; p<0.001). Importantly, the benefits were almost identical in patients with and without diabetes. It was the first evidence of a benefit of a SGLT2 inhibitor in heart failure, and Ahmad et al. anticipate that SGLT-2 inhibitors will play a major role in the treatment of heart failure in the near future.4 Another study of DAPA-HF indicated that the beneficial effect of SGLT2 inhibitors was similar in subgroups of all ages, including elderly patients, in whom the incidence of heart failure is higher.27

The EMPEROR-Reduced study showed that patients in the empagliflozin group were found to have a lower risk of cardiovascular death or heart-related hospitalisation compared with the control group, regardless of whether or not they had diabetes.28 The evidence of this trial added to the previous results of DAPA-HF, and was examined in a recent meta-analysis by Zannad et al.29 They found that the effects of both dapagliflozin and empagliflozin were consistent in lowering hospitalisation for heart failure with reduced ejection fraction patients. They suggested that these agents also improve renal outcomes and reduce all-cause and cardiovascular death. This study attracted media and medical attention, with many agreeing that the results of DAPA-HF and EMPEROR-Reduced substantially strengthened the rationale for the use of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction.30

There are currently two ongoing trials with gliflozins for heart failure with preserved ejection fraction: EMPEROR-Preserved and DELIVER. The results of both trials are expected to be presented in late 2021/early 2022.


Ahmad et al.’s review includes an in-depth analysis of the adverse effects of GLP-1 and SGLT2 drugs.4 GLP-1 receptor agonists are relatively safe, and most common side-effects are transient nausea and vomiting, especially when initiating therapy or up-titrating the dose. For SGLT2 inhibitors, an increase in the risk of genital mycotic infections has been reported, and more rarely, haemoconcentration.31


New drugs originally developed for the treatment of diabetes are showing consistent benefits in cardiovascular disease, including MACE and heart failure with reduced ejection fraction. Currently, the main evidence comes from trials using SGLT2 inhibitors in patients with and without diabetes and those investigating GLP-1s in people with diabetes. Ongoing trials will confirm if more GLP-1 and SGLT2 drugs have the same benefits, and if the results are similar for patients with heart failure with preserved ejection fraction. These findings will be important for cardiologists and diabetologists.


  1. Scherer PE, Hill JA. Obesity, diabetes, and cardiovascular diseases: a compendium. Circ Res 2016;118:1703–5.
    Crossref | PubMed
  2. Patel RB, Al Rifai M, McEvoy JW, et al. Implications of specialist density for diabetes care in the United States. JAMA Cardiol 2019;4:1174–5.
    Crossref | PubMed
  3. McGuire DK, Marx N, Johansen OE, et al. FDA guidance on antihyperglycaemic therapies for type 2 diabetes: one decade later. Diabetes Obes Metab 2019;21:1073–78.
    Crossref | PubMed
  4. Ahmad T, Riello RJ, Inzucchi SE. A practical guide for cardiologists to the pharmacological treatment of patients with type 2 diabetes and cardiovascular disease. Eur Cardiol 2021;16:e11.
  5. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 29 January 2018. CPMP/EWP/1080/00 Rev. 2.
  6. Lipska KJ, Krumholz HM. Is hemoglobin A1c the right outcome for studies of diabetes? JAMA 2017;317:1017–8.
    Crossref | PubMed
  7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71.
    Crossref | PubMed
  8. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38.
    Crossref | PubMed
  9. Zinman B, Wanner C, Lachin JM, et al. E-RO. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28.
    Crossref | PubMed
  10. Correia LC, Latado A, Porzsolt F. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:1797–9.
    Crossref | PubMed
  11. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841–51.
    Crossref | PubMed
  12. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228–39.
    Crossref | PubMed
  13. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247–57.
    Crossref | PubMed
  14. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519–29.
    Crossref | PubMed
  15. Li Y, Rosenblit P. Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect? Curr Cardiol Rep 2018;20:113.
    Crossref | PubMed
  16. Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776–85.
    Crossref | PubMed
  17. Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc 2020;9:e014908.
    Crossref | PubMed
  18. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28.
    Crossref | PubMed
  19. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–34.
    Crossref | PubMed
  20. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57.
    Crossref | PubMed
  21. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57.
    Crossref | PubMed
  22. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31–9.
    Crossref | PubMed
  23. Cannon CP, McGuire DK, Cherney D, et al. Results of the eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (VERTIS CV). Presented at: 80th American Diabetes Association Scientific Sessions, 16 June 2020.
  24. Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol 2018;71:2628–39.
    Crossref | PubMed
  25. Kosiborod M, Cavender MA, Fu AZ, et al. Response by Kosiborod et al to Letters Regarding Article, “Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”. Circulation 2018;137:989–91.
    Crossref | PubMed
  26. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008.
  27. Martinez FA, Serenelli M, Nicolau J, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age. Circulation 2019;141:100–11.
    Crossref | PubMed
  28. Packer M, Anker S, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–24.
    Crossref | PubMed
  29. Zannad F, Ferreira J, Pocock S, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819–29.
    Crossref | PubMed
  30. Jarcho J. More evidence for SGLT2 inhibitors in heart failure. N Engl J Med 2020;383:1481–2.
    Crossref | PubMed
  31. Donnan JR, Grandy CA, Chibrikov E, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open 2019;9:e022577.
    Crossref | PubMed